UK – MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

MSD’s – known as Merck & Co in the US and Canada – Keytruda (pembrolizumab) in combination with Eisai’s Lenvima (lenvatinib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat certain patients with endometrial cancer.

The combination therapy is specifically indicated for adults with advanced or recurrent endometrial cancer whose disease has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy.

The incidence of all womb cancers in the UK has increased by 12% in the last ten years, with over 9,700 people diagnosed with some form of the disease every year.

Endometrial carcinoma is the most common type of womb cancer, and while it often has a better prognosis than other womb cancers if diagnosed early, patients with advanced or recurrent disease face limited treatment options and short survival times…